Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

644 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Changes in virologic markers as predictors of CD4 cell decline and progression of disease in human immunodeficiency virus type 1-infected adults treated with nucleosides. AIDS Clinical Trials Group Protocol 175 Team.
Fiscus SA, Hughes MD, Lathey JL, Pi T, Jackson B, Rasheed S, Elbeik T, Reichman R, Japour A, Byington R, Scott W, Griffith BP, Katzenstein DA, Hammer SM. Fiscus SA, et al. Among authors: rasheed s. J Infect Dis. 1998 Mar;177(3):625-33. doi: 10.1086/514248. J Infect Dis. 1998. PMID: 9498441 Clinical Trial.
Variability and prognostic values of virologic and CD4 cell measures in human immunodeficiency virus type 1-infected patients with 200-500 CD4 cells/mm(3) (ACTG 175). AIDS Clinical Trials Group Protocol 175 Team.
Lathey JL, Hughes MD, Fiscus SA, Pi T, Jackson JB, Rasheed S, Elbeik T, Reichman R, Japour A, D'Aquila RT, Scott W, Griffith BP, Hammer SM, Katzenstein DA. Lathey JL, et al. Among authors: rasheed s. J Infect Dis. 1998 Mar;177(3):617-24. doi: 10.1086/514250. J Infect Dis. 1998. PMID: 9498440 Clinical Trial.
The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team.
Katzenstein DA, Hammer SM, Hughes MD, Gundacker H, Jackson JB, Fiscus S, Rasheed S, Elbeik T, Reichman R, Japour A, Merigan TC, Hirsch MS. Katzenstein DA, et al. Among authors: rasheed s. N Engl J Med. 1996 Oct 10;335(15):1091-8. doi: 10.1056/NEJM199610103351502. N Engl J Med. 1996. PMID: 8813039 Free article. Clinical Trial.
Multicenter evaluation of methods to quantitate human immunodeficiency virus type 1 RNA in seminal plasma.
Fiscus SA, Brambilla D, Coombs RW, Yen-Lieberman B, Bremer J, Kovacs A, Rasheed S, Vahey M, Schutzbank T, Reichelderfer PS; AIDS Clinical Trials Group Genital Secretions Working Group. Fiscus SA, et al. Among authors: rasheed s. J Clin Microbiol. 2000 Jun;38(6):2348-53. doi: 10.1128/JCM.38.6.2348-2353.2000. J Clin Microbiol. 2000. PMID: 10835001 Free PMC article. Clinical Trial.
Evaluation of an infectivity standard for real-time quality control of human immunodeficiency virus type 1 quantitative micrococulture assays. Participating Laboratories of The AIDS Clinical Trials Group.
Scott WA, Brambilla D, Siwak E, Beatty C, Bremer J, Coombs RW, Farzadegan H, Fiscus SA, Hammer SM, Hollinger FB, Khan N, Rasheed S, Reichelderfer PS. Scott WA, et al. Among authors: rasheed s. J Clin Microbiol. 1996 Sep;34(9):2312-5. doi: 10.1128/jcm.34.9.2312-2315.1996. J Clin Microbiol. 1996. PMID: 8862609 Free PMC article.
Optimization of quantitative culture assay for human immunodeficiency virus from plasma. Plasma Viremia Group Laboratories of the AIDS Clinical Trials Group (National Institute of Allergy and Infectious Diseases).
Lathey JL, Fiscus SA, Rasheed S, Kappes JC, Griffith BP, Elbeik T, Spector SA, Reichelderfer PS. Lathey JL, et al. Among authors: rasheed s. J Clin Microbiol. 1994 Dec;32(12):3064-7. doi: 10.1128/jcm.32.12.3064-3067.1994. J Clin Microbiol. 1994. PMID: 7883903 Free PMC article.
Evaluation of pharmacokinetics, safety, tolerance, and activity of combination of zalcitabine and zidovudine in stable, zidovudine-treated pediatric patients with human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 190 Team.
Bakshi SS, Britto P, Capparelli E, Mofenson L, Fowler MG, Rasheed S, Schoenfeld D, Zimmer B, Frank Y, Yogev R, Jimenez E, Salgo M, Boone G, Pahwa SG. Bakshi SS, et al. Among authors: rasheed s. J Infect Dis. 1997 May;175(5):1039-50. doi: 10.1086/520351. J Infect Dis. 1997. PMID: 9129064 Clinical Trial.
Evaluation of a quality assurance program for quantitation of human immunodeficiency virus type 1 RNA in plasma by the AIDS Clinical Trials Group virology laboratories.
Yen-Lieberman B, Brambilla D, Jackson B, Bremer J, Coombs R, Cronin M, Herman S, Katzenstein D, Leung S, Lin HJ, Palumbo P, Rasheed S, Todd J, Vahey M, Reichelderfer P. Yen-Lieberman B, et al. Among authors: rasheed s. J Clin Microbiol. 1996 Nov;34(11):2695-701. doi: 10.1128/jcm.34.11.2695-2701.1996. J Clin Microbiol. 1996. PMID: 8897167 Free PMC article.
Serum p24 antigen level as an intermediate end point in clinical trials of zidovudine in people infected with human immunodeficiency virus type 1. Aids Clinical Trials Group Virology Laboratories.
DeGruttola V, Beckett LA, Coombs RW, Arduino JM, Balfour HH Jr, Rasheed S, Hollinger FB, Fischl MA, Volberding P. DeGruttola V, et al. Among authors: rasheed s. J Infect Dis. 1994 Apr;169(4):713-21. doi: 10.1093/infdis/169.4.713. J Infect Dis. 1994. PMID: 8133085 Clinical Trial.
644 results